Survival in gastric adenocarcinoma patients after adjuvant treatment in the Colombian National Institute of Cancerology during 2009.
Keywords:
Gastric tumors, Adjuvant chemotherapy, Combined treatment, Survival, Survival analysis, MortalityAbstract
Objective: To determine the disease free and overall survival at two years in patients with gastric cancer who received adjuvant treatment in the Colombian National Institute of Cancerology (INC) during 2009.
Patients and methods: A retrospective study was conducted on patients with a diagnosis of a gastric adenocarcinoma or of the gastroesophageal junction and who had received adjuvant chemotherapy in the INC during the year 2009. The variables recorded were: clinical and epidemiological characteristics, treatment received, and the overall and disease free survival at two years.
Results: A total of 32 patients (56.2% males), with a mean age of 55 years were included in the analysis. The most predominant histological sub-type was intestinal (53.1%). T3-T4 tumor invasion grade was present in 81.2%, and lymph involvement in 84.3%, with 34.3% of cases with seven or more lymph nodes involved. Almost all of them (96.8%) received adjuvant treatment according to the Macdonald protocol. Three-quarters (75%) of the patients completed the treatment. Treatment was stopped in 12% of cases due to toxicity. The mean follow-up of the patients was 37.8 months. The overall and disease free survival was at two years in the patients who received adjuvant chemotherapy was 85.18% and 77.4%, respectively.
Conclusions: The study showed a greater overall and disease free survival in patients who received adjuvant treatment in the INC compared to that found in patients in the INT 0116 and MAGIC studies. The survival is similar to that in studies with Asiatic populations.
Author Biographies
Fabio Grosso, Instituto Nacional de Cancerología
Grupo de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá D. C., Colombia
Ricardo Brugés, Instituto Nacional de Cancerología
Grupo de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá D. C., Colombia
Licet Villamizar, Instituto Nacional de Cancerología
Grupo de Investigación clínica, Instituto Nacional de Cancerología, Bogotá D. C., Colombia
References
Jemal A, Bray F, Center MM, Ferlay J , Ward E , Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
https://doi.org/10.3322/caac.20107
Hyatt BJ, Paull PE, Wassef W. Gastric oncology: an update. Curr Opin Gastroenterol. 2009;25:570-8.
https://doi.org/10.1097/MOG.0b013e328331b5c9
Hamilton SR, Aaltonen LA, Cancer IAfRo, Organization WH. Pathology and genetics of tumours of the digestive system. Lyon: IARC; 2000.
Ott K, Lordick F, Blank S, Buchler M. Gastric cancer: surgery in 2011. Langenbecks Arch Surg. 2011;396:743-58.
https://doi.org/10.1007/s00423-010-0738-7
Jiang Y, Ajani JA. Multidisciplinary management of gastric cancer. Curr Opin Gastroenterol. 2010;26:640-6.
https://doi.org/10.1097/MOG.0b013e32833efd9b
Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005;241:27-39.
https://doi.org/10.1097/01.sla.0000149300.28588.23
Verdecchia A, Mariotto A, Gatta G, Bustamante-Teixeira MT, Ajiki W. Comparison of stomach cancer incidence and survival in four continents. Eur J Cancer. 2003;39:1603-9.
https://doi.org/10.1016/S0959-8049(03)00360-5
Patel SH, Kooby DA. Gastric adenocarcinoma surgery and adjuvant therapy. Surg Clin North Am. 2011;91:1039-77.
https://doi.org/10.1016/j.suc.2011.06.009
Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: 5th Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer. 2000;88:921-32.
https://doi.org/10.1002/(SICI)1097-0142(20000215)88:4<921::AID-CNCR24>3.0.CO;2-S
Novotny AR , Schuhmacher C , Busch R , Kattan MW , Brennan MF, Siewert JR. Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe. Ann Surg. 2006;243:74-81.
https://doi.org/10.1097/01.sla.0000194088.81126.85
Nagata T, Ichikawa D, Komatsu S, et al. Prognostic impact of microscopic positive margin in gastric cancer patients. J Surg Oncol. 2011;104:592-7.
https://doi.org/10.1002/jso.22022
Youn HG , AnJ Y, Choi MG , Noh JH , Sohn TS , Kim S. Recurrence after curative resection of early gastric cancer. Ann Surg Oncol. 2010;17:448-54.
https://doi.org/10.1245/s10434-009-0772-2
Kim JH, Jang YJ, Park SS, Park SH, Mok YJ. Benefit of post-operative surveillance for recurrence after curative resection for gastric cancer. J Gastrointest Surg. 2010;14:969-76.
https://doi.org/10.1007/s11605-010-1200-4
Chang AT, Ng WT, Law AL, Ku KM, Lee MC, Lee AW. Adjuvant chemoradiation for resected gastric cancer: a 10-year experience. Gastric Cancer. 2011;14:63-71.
https://doi.org/10.1007/s10120-011-0011-y
Li F, Zhang R, Liang H, Liu H, Quan J. The pattern and risk factors of recurrence of proximal gastric cancer after curative resection. J Surg Oncol. 2013;107:130-5.
https://doi.org/10.1002/jso.23252
Wang SY, Yeh CN, Lee HL, et al. Clinical impact of positive surgical margin status on gastric cancer patients undergoing gastrectomy. Ann Surg Oncol. 2009;16:2738-43.
https://doi.org/10.1245/s10434-009-0616-0
Kovoor PA, Hwang J. Treatment of resectable gastric cancer: current standards of care. Expert Rev Anticancer Ther. 2009;9:135-42.
https://doi.org/10.1586/14737140.9.1.135
Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303:1729-37.
https://doi.org/10.1001/jama.2010.534
Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol. 2000;11:837-43.
https://doi.org/10.1023/A:1008377101672
Sun P, Xiang JB, Chen ZY. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg. 2009;96:26-33.
https://doi.org/10.1002/bjs.6408
Zhao SL, Fang JY. The role of postoperative adjuvant chemotherapy following curative resection for gastric cancer: a meta-analysis. Cancer Invest. 2008;26:317-25.
https://doi.org/10.1080/07357900701834686
Liu TS, Wang Y, Chen SY, Sun YH. An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer. Eur J Surg Oncol. 2008;34:1208-16.
https://doi.org/10.1016/j.ejso.2008.02.002
Oba K. Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: update of a meta-analysis. Int J Clin Oncol. 2009;14:85-9.
https://doi.org/10.1007/s10147-009-0877-4
Morabito A, Carillio G, Longo R. Systemic treatment of gastric cancer. Crit Rev Oncol Hematol. 2009;70:216-34.
https://doi.org/10.1016/j.critrevonc.2008.08.005
Okines AF , Cunningham D . Multimodality treatment for localized gastro-oesophageal cancer. Ann Oncol. 2010;21(Suppl 7):vii286-93.
https://doi.org/10.1093/annonc/mdq282
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.
https://doi.org/10.1002/ijc.25516
Correa P, Piazuelo MB. Gastric cancer: The colombian enigma. Rev Colomb Gastroenterol. 2010;25:334-7.
Otero Regino W. Cáncer gástrico en Colombia: un diagnóstico tardío que amerita el compromiso del Estado. Rev Colomb Gastroenterol. 2008;23:302-4.
República de Colombia, Instituto Nacional de Cancerología. Cáncer en cifras [internet]. 2012 [consultado 5 Mar 2013]. Disponible en: http://www.cancer.gov.co/contenido/contenido.aspx?catID=434&conID=790&pagID=774
Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-30.
https://doi.org/10.1056/NEJMoa010187
Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30:2327-33.
https://doi.org/10.1200/JCO.2011.36.7136
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
https://doi.org/10.1056/NEJMoa055531
Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-20.
https://doi.org/10.1056/NEJMoa072252
Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387-93.
https://doi.org/10.1200/JCO.2011.36.5908
Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315-21.
https://doi.org/10.1016/S0140-6736(11)61873-4
Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268-73.
https://doi.org/10.1200/JCO.2011.39.1953
Macdonald JS. Gastriccancer: Nagoyaisnot New York . JClin Oncol. 2011;29:4348-50.
Brooks GA , Enzinger PC , Fuchs CS . Adjuvant therapy for gastric cancer: revisiting the past to clarify the future. J Clin Oncol. 2012;30:2297-9.
https://doi.org/10.1200/JCO.2012.42.4069
Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439-49.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
